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Background: Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome
15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic
variants also predict nicotine dependence and delayed smoking cessation. It is unclear whether smoking cessa-
tion confers the same beneﬁts in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants
versus those who do not.
Methods:Meta-analyses examined the association between smoking cessation and lung cancer risk in 15 studies
of individuals with European ancestrywho possessed varying rs16969968 genotypes (N=12,690 ever smokers,
including 6988 cases of lung cancer and 5702 controls) in the International Lung Cancer Consortium.
Results: Smoking cessation (former vs. current smokers) was associated with a lower likelihood of lung cancer
(OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015). Among lung cancer patients, smoking cessation was associated
with a 7-year delay in median age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.61–0.77, p = 4.9 ∗ 10–10).
The CHRNA5 rs16969968 risk genotype (AA)was associatedwith increased risk and earlier diagnosis for lung can-
cer, but the beneﬁcial effects of smoking cessation were very similar in those with andwithout the risk genotype.
Conclusion:We demonstrate that quitting smoking is highly beneﬁcial in reducing lung cancer risks for smokers
regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on aver-
age, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of
lung cancer in half and delaying its onset by 7 years for those who develop it. These results: 1) underscore the
potential value of smoking cessation for all smokers, 2) suggest that CHRNA5 rs16969968 genotype affects lung
cancer diagnosis through its effects on smoking, and 3) have potential value for framing preventive interventions
for those who smoke.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Cigarette smoking is the leadingmodiﬁable risk for cancer and mul-
tiple major chronic illnesses. Growing evidence identiﬁes that genetic
variation in the α5 nicotinic cholinergic receptor subunit (CHRNA5)
gene plays a key role in both heavy smoking and nicotine dependence
(Bierut et al., 2007; Bierut et al., 2008a). Multiple large meta-analyses
demonstrated the association with smoking quantity, deﬁned by num-
ber of cigarettes smoked per day (CPD) (Liu et al., 2010; Saccone et al.,
2010; TAG, 2010; Thorgeirsson et al., 2010), with themost robust signal
for two highly correlated genetic variants, rs16969968 and rs1051730
in subjects of European ancestry (TAG, 2010). The coding variant,
rs16969968, results in an amino acid change in theα5 nicotinic cholin-
ergic receptor subunit, and subsequently alters nicotinic receptor con-
ductance in vitro (Bierut et al., 2008b; Kuryatov et al., 2011). Genetic
variation in CHRNA5 increases risk for smoking-related disorders such
as lung cancer and chronic obstructive pulmonary disease (COPD)
(Amos et al., 2008; Pillai et al., 2009; Thorgeirsson et al., 2008). Research
suggests that the association between CHRNA5 and lung cancer may be
mediated by COPD (Young et al., 2011; Brennan et al., 2011;Wang et al.,
2010). Further, CHRNA5 has been reported to predict smoking cessation
in both cessation trials (Baker et al., 2009; Bergen et al., 2013; Chen et
al., 2012; Munafo et al., 2011; Sarginson et al., 2011) and general popu-
lation studies (TAG, 2010; Chen et al., 2012; Chen et al., 2015a). The
CHRNA5 variant rs16969968 was recently shown to be a marker of de-
layed smoking cessation in a meta-analysis (Chen et al., 2015a).
Smokerswith the high-risk genotype had delayed age of smoking cessa-
tion compared with those with the low-risk genotype (age 56 versus
age 52). Similarly, those with the high-risk genotype had a 4-year earli-
er age of lung cancer diagnosis compared to those with the low-risk
genotypes (age 61 vs. age 65).
Although it is clear that smoking cessation reduces cancer risk (Jha et
al., 2013), and that CHRNA5 risk variants affect both smoking heaviness
and duration, it is unclear whether CHRNA5 alters the health beneﬁts of
smoking cessation. For example, the CHRNA5 high-risk variants may
directly affect lung cancer risk or, instead, inﬂuence risk via effects on
smoking heaviness and cessation (Amos et al., 2008; Thorgeirsson
et al., 2008; Ji et al., 2015; Tseng et al., 2014; Wang et al., 2012; Hung
et al., 2008a). In the ﬁrst case, smoking cessation would have negligible
effects on lung cancer latency or risk among those with the high-risk
variants. Smokers with such risk variants may have smoked so
intensively prior to quitting, that cessation confers lesser beneﬁt for
them (in terms of lung cancer onset or likelihood). Conversely, smokers
with low-risk genotypes may not beneﬁt as much from cessation be-
cause they might have low genetic risk for lung cancer in addition to
their lower risk for heavy smoking.
Large epidemiologic studies have shown the clear beneﬁts of
smoking cessation in reducing mortality and morbidity (Jha et al.,
2013), but no studies have examined whether such beneﬁts vary
based on a smoker's genotype. Certainly, cessation has the potential to
beneﬁt almost any smoker, but discovering that some smokers may es-
pecially beneﬁt from cessation could not only elucidate the nature of the
mechanism(s) linking CHRNA5 to lung cancer, but might, also, inform
personalized prevention efforts. For instance, such ﬁndings might en-
courage directing some smokers to additional preventive interventions
and might be used to support “gain framed” messaging for such
smokers, an approach to prevention with especially strong supporting
evidence (Gallagher and Updegraff, 2012).
The CHRNA5 risk variants were chosen for this study because they
are associated with lung cancer risk and onset, with exposure to a pri-
mary cancer etiologic factor (smoking duration and heaviness), and
with the effects of a preventive action (smoking cessation). Therefore,
they have the potential to elucidate the relations among genetic risk,
etiologic factors, and preventive actions.
To address the gap in knowledge concerning CHRNA5, smoking
cessation, and lung cancer risk, we meta-analyzed results from 15
European ancestry samples in the International Lung Cancer Consor-
tium (ILCCO) and Transdisciplinary Research in Cancer of the Lung
(TRICL). We explored two linked aims: 1) Do both CHRNA5 genetic
risk and smoking cessation independently affect the risk of lung cancer?
2) Does the effect of smoking cessation on the risk of lung cancer vary
with variation in CHRNA5? i.e., does the effect of smoking cessation on
lung cancer risk and onset differ as a function of CHRNA5 rs16969968
genotype?
2. Methods
2.1. Samples
This is a collaborative meta-analysis based on the International Lung
Cancer Consortium (ILCCO) and Transdisciplinary Research in Cancer of
the Lung (TRICL) which were established with the aim of sharing
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comparable data from ongoing case-control and cohort studies of lung
cancer. (Hung et al., 2008b; Timofeeva et al., 2012). To examine
CHRNA5, smoking cessation, and lung cancer, we invited all ILCCO and
TRICL studies of individuals of European Ancestry, of which, 15 (out of
27 invited studies) participated in the collaborative meta-analysis and
pooled analysis with shared individual-level data. Results from 15 case
control studies of lung cancer (N= 12,690 unrelated smokers of Euro-
pean ancestry) contributed to the meta-analyses. Informed consent
was obtained from participants, and all studies received approval from
the appropriate institutional review boards. To be included in analyses,
each subject was required to be an ever-smoker (N100 cigarettes in his
or her lifetime). Tables S1, S2, and Text S1 provide additional details for
each study.
With the aim of studying smoking cessation, CHRNA5, and lung
cancer risk, we invited all ILCCO and TRICL studies of individuals of
European Ancestry and 15 (out of 27 invited studies) participated in
the collaborative meta-analysis and pooled analysis with shared indi-
vidual-level data.
2.2. Outcomes
The primary outcomes of the analyses were: 1) case vs. control sta-
tus for lung cancer in the combined sample of cases and controls, and
2) time (in years) from birth to lung cancer diagnosis among lung
cancer cases.
2.3. Variants for Analyses
Because of its biological signiﬁcance, we targeted the CHRNA5 vari-
ant rs16969968 for association testing. The variant rs16969968 was
available in all datasets except the Germany Study for which we used
a proxy variant (rs1051730, r2 =0.99 estimated based on 1000 Ge-
nomes for the EUR samples) for analyses because the imputed genotype
was not available (Altshuler et al., 2010;Durbin et al., 2010). In addition,
we conducted the meta-analyses with and without the Germany Study
and reached similar results.
2.4. Statistical Analyses and Meta-analyses
In each dataset, we used logistic regression and Cox regression
models to evaluate the association between rs16969968 and the two
primary outcomes: i.e., lung cancer case vs. control, and age of lung can-
cer diagnosis among the cases, respectively. Age as a continuous vari-
able and sex were included as covariates when appropriate. Additional
covariates included smoking quantity and pack years. Smoking quantity
when subjects smoked regularly was assessed with cigarettes smoked
per day (CPD), deﬁned as a 4-level ordered trait (CPD ≤ 10;
11 ≤ CPD ≤ 20; 21 ≤ CPD ≤ 30; CPD ≥ 31, coded as 0, 1, 2, 3, respectively).
The variable “pack years”was deﬁned by the product of smoking dura-
tion and CPD, and was modeled via quartiles.
Genotypeswere coded additively as the number ofminor alleles (A),
where the reference allele was deﬁned as themajor allele (G) in the Eu-
ropean ancestry population (Sherry et al., 2001). Consistency of allelic
codingwas conﬁrmed by comparing allele labels and frequencies across
datasets (Table S2). Analyses were performed at Washington Universi-
ty, as individual-level data were available for both meta-analyses and
pooled analyses. Individual SNP analyses were performed using SAS
(SAS Institute, Cary, NC).
The R package, rmeta, was used to generate meta-analysis plots
(Lumley, 2012). We reported results from random effects models for
all meta-analyses. Heterogeneity across studies was assessed with the
Cochran Q test and resulting P values were reported for all analyses.
There was evidence of heterogeneity across datasets for the analyses
of the effect of smoking cessation on lung cancer, but not for the effect
of genotypes on lung cancer. This heterogeneity may be due to the
varying study designs and ascertainment strategies. Heterogeneity re-
sults for all meta-analysis are listed in Table S3.
3. Results
We examined individuals who ever smoked at least 100 cigarettes
(5833 current and 6857 former smokers) from 15 case-control studies
of lung cancer. CHRNA5 rs16969968 is known to predict risk for lung
cancer and delayed smoking cessation based on previous reports of
overlapping samples including these studies (Hung et al., 2008a; Chen
et al., 2015a). We hypothesized that smoking cessation is associated
with a decreased likelihood of lung cancer and delayed onset of lung
cancer in this sample. Further, we investigated whether the association
of smoking cessation and lung cancer risk varied with rs16969968 ge-
notype risk levels.
3.1. As Previously Reported, CHRNA5 rs16969968 Predicts Lung Cancer and
Earlier Diagnosis of Lung Cancer
First, we conﬁrmed a consistent association as previously reported
(Hung et al., 2008a; Chen et al., 2015a) between CHRNA5 rs16969968
and 1) increased likelihood of lung cancer when comparing cases and
controls of lung cancer (meta-analysis OR = 1.29, 95%CI = 1.21–1.38,
p=3.5 ∗ 10–13, PHeterogeneity = 0.196, see Fig. S1;this genetic association
does not vary signiﬁcantly with smoking quantity), and 2) earlier
diagnosis of lung cancer among cases of lung cancer (meta-analysis
HR = 1.07, 95%CI = 1.03–1.11, p = 1.1 ∗ 10–4, PHeterogeneity = 0.561,
see Fig. S2).
3.2. Quitting Smoking Decreases Risk Of Lung Cancer - Effect does not Vary
With rs16969968 Genotypes
In these case control studies, current smoking statuswas ascertained
simultaneously with case or control status for lung cancer. Ever-
smokers who reported having quit smoking N1 year prior to the cancer
diagnosis were deﬁned as former smokers; ever smokers who reported
active smoking were deﬁned as current smokers. The effect of smoking
cessation was deﬁned as the comparison of former vs. current smokers.
Among ever smokers, smoking cessation was associated with a lower
likelihood of lung cancer (OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015,
PHeterogeneity b 10–16). Both smoking cessation and rs16969968were sig-
niﬁcantly associated with lung cancer risk (Fig. 1, Fig. S1).
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
GG GA AA
Current Smokers
(N=5,833)
Former smokers
(N=6,857)
CHRNA5 rs16969968
Odds Ratio 
for 
lung cancer
Fig. 1. CHRNA5 rs16969968 predicts risk of lung cancer. Smoking cessation decreases
probability of lung cancer regardless of CHRNA5 rs16969968 genotype. Quit: individuals
who report having quit smoking when ascertained as cases of lung cancer or controls.
N = 12,690 (6988 cases of lung cancer and 5702 controls). All participants have smoked
at least 100 cigarettes (5833 active smokers, 6857 smokers who have quit). Adjusted for
age, sex and rs16969968 genotype.
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The effect of smoking cessation on lung cancer risk remained after
additionally adjusting for smoking quantity or pack years, and smoking
cessation remained a predictor of lower risk of lung cancer diagnosis
(OR=0.46, 95%CI= 0.29–0.74, p=0.0013 adjusted for smoking quan-
tity) When adjusting for pack years, the effect size point estimate was
similar (OR=0.47, 95%CI=0.14–1.52, p=0.21) although it did not ap-
proach statistical signiﬁcance as data on pack years were available for
only a subset of the studies).
Further, we examined whether this association varied in individuals
with different rs16969968 genotypes and found that smoking cessation
was signiﬁcantly associated with lower lung cancer risks for all
genotypes (GG: OR = 0.48, 95%CI = 0.30–0.77, p = 0.0024,
PHeterogeneity b 10–16; GA: OR = 0.46, 95%CI = 0.28–0.76, p = 0.0025,
PHeterogeneity b 10–16; AA: OR = 0.56, 95%CI = 0.34–0.91, p = 0.019,
PHeterogeneity = 3.36 ∗ 10–6) (Fig. S1). Genotype did not modify the effect
of smoking cessation on decreased risk of lung cancer among ever
smokers, and there was no interaction (OR = 1.01, 95%CI = 0.86–
1.18, p = 0.93, PHeterogeneity = 0.139, Fig. S1). The ﬁnding remained ro-
bust in the sensitivity analyses when all possible sets of studies (up to
N= 10) were excluded from the meta-analysis.
In addition, we obtained similar results in pooled analysis using
available individual-level data adjusted for age, sex, rs16969968 geno-
type, and study, and found that smoking cessation was associated
with decreased risk of lung cancer (N = 12,690, OR = 0.78, 95%CI =
0.75–0.91, P = 5.65 ∗ 10–31), and that genotype did not interact with
smoking cessation in predicting lung cancer likelihood (i.e., the beneﬁ-
cial effect of smoking cessation did not vary with rs16969968 genotype
(OR = 0.99, 95%CI = 0.94–1.05, P = 0.887)).
3.3. Quitting Smoking Delays Lung Cancer and This Effect Does not Vary
With CHRNA5 rs16969968 Genotype
Among ever smokers who were diagnosed with lung cancer,
smoking cessation was associated with delayed age of diagnosis,
adjusted for sex and rs16969968 (HR = 0.68, 95%CI = 0.61–0.77,
p = 4.9 ∗ 10–10, PHeterogeneity = 2.87 ∗ 10–8, see Fig. S2). Both smoking
cessation and rs16969968 were independent predictors of age of lung
cancer diagnosis. The median age at lung cancer diagnosis was 59 years
for current smokers, which was a 7-year earlier onset compared to for-
mer smokers, who had a median age of diagnosis of 66 years (Fig. 2).
The effect of smoking cessation on age of lung cancer diagnosis
remained after additionally adjusting for cigarettes smoked per day, or
pack years, and smoking cessation remained a signiﬁcant predictor of
a delayed age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.60–
0.76, p = 1.4 ∗ 10–10, adjusted for cigarettes smoked per day; HR =
0.62, 95%CI= 0.46–0.85, p=0.0032, adjusted for pack years for studies
with the information).
We examined whether this association varies by genotype and
found that smoking cessation was associated with delayed age of lung
cancer diagnosis for all genotypes (GG: HR = 0.70, 95%CI = 0.61–
0.82, p = 5.2 ∗ 10–6, PHeterogeneity = 0.002; GA: HR = 0.63, 95%CI =
0.55–0.72, p = 7.8 ∗ 10–12, PHeterogeneity = 0.001; AA: HR = 0.66,
95%CI = 0.57–0.76, p = 1.3 ∗ 10–8, PHeterogeneity = 0.344) (Fig. S2).
Even though CHRNA5 rs16969968 risk genotypes were associated
with delayed quitting and earlier age of lung cancer diagnosis as previ-
ously reported (Chen et al., 2015a), genotypes did not modify the effect
of smoking cessation on the delayed age of lung cancer diagnosis and
median diagnosis age rs16969968
GG GA AA
65 64 61
median diagnosis age
Active smoking 59
Having quit 66
median diagnosis age rs16969968
GG GA AA
Active smoking 60 59 58
Having quit 67 66 65
59
66
65 64 61
Fig. 2. CHRNA5 rs16969968 predicts earlier lung cancer. Smoking cessation delays lung cancer, regardless of CHRNA5 rs16969968 genotype. Quit: individuals who report having quit
smoking when ascertained as cases of lung cancer. N = 6,988 cases of lung cancer who are ever smokers. (3,471 current smokers, 3,517 former Smokers. Adjusted for sex, study, and
rs16969968 genotype.
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there was no interaction (HR = 0.98, 95%CI = 0.91–1.05, p = 0.57,
PHeterogeneity = 0.542, Fig. S2). The ﬁnding remained robust in the sensi-
tivity analyses when all possible sets (up to N = 10) of studies were
excluded from the meta-analysis.
The median ages of lung cancer diagnosis for current and former
smokers of different genotypes are in Fig. 3. Smokers with the high-
risk AA genotypes, compared with those with the low-risk GG geno-
types, have earlier age of lung cancer diagnosis, but this risk is greatly
reduced by successful smoking cessation. Individuals with the high-
risk genotype who have quit smoking have a mean age of lung cancer
diagnosis of 65 vs. a mean age of 58 for those who continue to smoke.
Individuals with the low-risk genotype who have quit smoking have a
mean age of lung cancer diagnosis of 67 vs. a mean age of 60 for who
continue smoking.
In addition, we reached similar conclusions in pooled analysis using
available individual-level data adjusted for sex, rs16969968, and study;
we found that smoking cessation was associated with delayed lung
cancer diagnosis (N = 6988,HR = 0.62, 95%CI = 0.59–0.65, P =
1.26 ∗ 10–77), and this association did not vary with rs16969968 geno-
type (HR = 1.00, 95%CI = 0.94–1·07, P= 0.958).
4. Discussion
Genetic information is increasingly used by both patients and pro-
viders to determine health risks. Multiple meta-analyses have shown
that the nicotinic receptor variant, CHRNA5 rs16969968, predicts
heavy smoking (Liu et al., 2010; Saccone et al., 2010; TAG, 2010;
Thorgeirsson et al., 2010), delayed quitting (TAG, 2010; Baker et al.,
2009; Bergen et al., 2013; Chen et al., 2012; Munafo et al., 2011;
Sarginson et al., 2011; Chen et al., 2015a), and earlier onset and higher
probability of lung cancer (Amos et al., 2008; Thorgeirsson et al.,
2008; Chen et al., 2015a; Hung et al., 2008a; Lips et al., 2010; Spitz
et al., 2008). It is important to determine how malleable these genetic
risks are to preventive or treatment efforts. For example,will individuals
with high-risk genetic variants for lung cancer beneﬁt from known ef-
fective preventive measures such as smoking cessation? In essence, do
genetically high-risk and low-risk individuals experience different
levels of beneﬁt from cessation? Evidence related to this issue could
both further elucidate the inﬂuences on cancer, and also serve as a
basis for genetically informed preventive intervention. This is a large
meta-analysis to examine the beneﬁt of smoking cessation for lung
cancer in individuals with different CHRNA5 rs16969968 genotypes.
Obviously, these results cannot be extrapolated to the effects of other
genotypes or other preventive actions (i.e., different from smoking
cessation).
We found that smoking cessation is beneﬁcial in reducing and
delaying lung cancer and this beneﬁcial effect does not vary with
CHRNA5 rs16969968,which is a geneticmarker for nicotinedependence
(Liu et al., 2010; Saccone et al., 2010; TAG, 2010; Thorgeirsson et al.,
2010), lung cancer (Amos et al., 2008; Thorgeirsson et al., 2008),
COPD (Pillai et al., 2009), and delayed quitting (Chen et al., 2015a).
Even though the CHRNA5 variant, rs16969968, predicts a 4-year earlier
diagnosis of lung cancer among smokers with the high-risk genotypes
vs. the low-risk genotypes (Chen et al., 2015a), quitting smoking is a
highly effective preventive measure, cutting lung cancer risk approxi-
mately in half for individuals with all genotypes. Furthermore, among
those who developed lung cancer, quitting smoking delayed diagnosis
by 7 years (from 59 years of age for active smokers to 66 years of age,
Fig. 2), with the delay not differing by genotype.
By simultaneously studying both genetic risk and preventive action
(cessation), this study provides an informative perspective on compar-
ative risk. For instance, it is clear that the effect of smoking cessation is
larger than the effect of CHRNA5 rs16969968 genotypes on the risk of
lung cancer. Smokers with the high-risk genotype, compared with
those with the low-risk genotype, do have an increased risk for lung
cancer, but this risk can be greatly reduced if they successfully quit
smoking. In fact, smokers with the high-risk genotype who quit have
lower risk than those with the low-risk genotypes who continue
smoking (i.e., individuals with the high-risk genotype who have quit
smoking have a mean age of lung cancer diagnosis of 65 vs. a mean
age of 60 for smokerswith a low-risk genotypewho continue smoking).
The mechanisms through which CHRNA5 increases the risk for, and
accelerates the onset age of, lung cancer likely involve multiple direct
or indirect pathways (mediated through cigarette smoking (Liu et al.,
2010; Saccone et al., 2010; TAG, 2010; Thorgeirsson et al., 2010), deeper
inhalation of cigarettes leading to higher carcinogen exposure (Bloom
et al., 2014; Le Marchand et al., 2008), and a delay in smoking cessation
(Chen et al., 2015a). There has been inconsistent evidence on whether
Fig. 3. Summary diagram of CHRNA5 rs16969968 genotypes, smoking cessation, and lung cancer risks. *These associations are based on existing evidence (Chen et al., 2015a, b).
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or not the genetic association of CHRNA5 and lung cancer is largely me-
diated through smoking) (Amos et al., 2008; Thorgeirsson et al., 2008; Ji
et al., 2015; Tseng et al., 2014; Wang et al., 2012; Hung et al., 2008a).
Some study suggests that CHRNA5 confers risk of lung and cardiovas-
cular diseases largely through an effect on behavior (Thorgeirsson et al.,
2008), while other studies suggest that an increased risk with CHRNA5
and lung cancer in non-smokers would indicate that the disease mech-
anism with lung cancer is unlikely to be explained by an association
with tobacco addiction. (Ji et al., 2015; Hung et al., 2008a) Most studies
suggest that CHRNA5 had both a direct effect on overall lung cancer risk
and an indirect effect through smoking. (Amos et al., 2008; Tseng et al.,
2014; Wang et al., 2012) Our ﬁnding that smoking cessation decreases
the elevated genetic risk for lung cancer supports the view that smoking
at least partially mediates the effect of this genetic risk. This evidence
suggests that the increased risk associated with high-risk genotypes
for lung cancer is at least partially attributed to the smoker's inability
to quit smoking relatively early (Chen et al., 2015a). For those who suc-
ceed in quitting, the elevated genetic risk for lung cancer conferred by
rs16969968 (AA genotypes: 30% more likely to get lung cancer and
4 year earlier diagnosis) can be reduced drastically, resulting in halving
the risk for lung cancer and delaying the age of diagnosis by 7 years.
These results should be interpreted in the context ofmultiple limita-
tions. First, smoking cessation in the samples was self-reported and not
assessedusingbiochemical conﬁrmation.However, research shows that
self-report is a valid indicator of current smoking, especially when there
are no strong incentives to deceive (Subcommittee on Biochemical
Veriﬁcation SRNT, 2002). Second, we compared current smokers and
former smokers based on the self-reported smoking status when cases
and controls for lung cancer were recruited. Caution is needed for re-
sults based on the cross-sectional nature of the data. For a small portion
of smokers (5.7%) who receive the lung cancer diagnosis and quit
smoking in the same year, it is unknown whether they quit before the
manifestation of disease or their diagnosis. We have repeated the
same analyses by including, excluding, or reclassifying their smoking
status and reached similar results. Third, this work analyzed only one
genetic variant, and it is clear that multiple genes or variants contribute
to lung cancer and smoking behaviors (Uhl et al., 2012). Fourth, we
found no signiﬁcant interaction between smoking cessation and
rs16969968 genotype on lung cancer risk, despite the non-linear trend
in point estimates of the effect of quitting across genotypes on lung can-
cer risk or age at diagnosis.With our sample size of 12,690 smokers and
the allele frequency of rs16969968, we have sufﬁcient power (0·8) to
detect an interaction effect size of 1.12. Clearly a larger sample size
would be needed to detect a smaller interaction. Fifth, this work ana-
lyzed the association between CHRNA5 and lung cancer, and it is possi-
ble that this association is mediated by other factors such as chronic
obstructive pulmonary disease (COPD) (Young et al., 2008). Finally,
this study included only subjects of European ancestry.
Lung cancer is the most common cancer in US and worldwide
(Centers for Disease Control and Prevention and National Center for
Health Statistics, 2013; American Cancer Society, 2014), and the surviv-
al rate is low (Howlader et al., 2013). Most cases (90%) of lung cancer
are attributable to smoking (General, 2014).We demonstrate that quit-
ting smoking is highly beneﬁcial in reducing lung cancer risks for
smokers regardless of their CHRNA5 rs16969968 genetic risk status. Ev-
idence suggest that relative to individuals with CHRNA5 rs16969968
low-risk genotypes, those with high-risk genotypes are likely to
smoke greater quantities, inhalemore deeply, havemore difﬁculty quit-
ting, and have higher risk for lung cancer (Bierut et al., 2007; Saccone et
al., 2010; TAG, 2010; Thorgeirsson et al., 2010; Thorgeirsson et al., 2008;
Chen et al., 2012; Chen et al., 2015a; Hung et al., 2008a; Bloom et al.,
2014).Wenowextend this evidence to show that quitting smoking pro-
duces essentially equivalent beneﬁt regardless of genotype for this ge-
netic risk factor. These results have potential value for preventive
counseling with smokers; smokers with high-risk CHRNA5 genotypes
can be informed that, on average, smokers with their genetic risk can
largely eliminate their elevated genetic risk for lung cancer by quitting
smoking. They can cut their risk of lung cancer in half and delay its
onset by 7 years, if they develop it. These results underscore the poten-
tial value of smoking cessation for all smokers, they elucidate the causal
path from CHRNA5 risk to lung cancer diagnosis, and they have potential
value for framing preventive interventions for those who smoke.
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